Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01527513
Recruitment Status : Completed
First Posted : February 7, 2012
Results First Posted : October 24, 2014
Last Update Posted : October 24, 2014
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.

Condition or disease Intervention/treatment Phase
Partial Epilepsy Drug: Eslicarbazepine acetate (BIA 2-093) Drug: Placebo Phase 2

Detailed Description:

This will be a 2-part multicentre study in approximately 117 patients. Part I of the study will consist of a 4-week prospective observational baseline period, a 12-week double-blind period (4-week up-titration and 8-week maintenance), and a tapering-off period.

After the screening visit (V1), patients will enter the baseline period. At the end of the baseline period (V2), eligible patients will be randomised in a ratio of 2:1 to receive double-blind treatment with Eslicarbazepine acetate or Placebo in addition to concomitant therapy with 1 or 2 Anti-Epileptic Drugs (AEDs). Concomitant AED therapy will be kept stable during the whole study.

Initial dose of the study treatment will be 10 mg/kg/day. After 2-weeks on 10 mg/kg/day, the dose will be up-titrated to 20 mg/kg/day (maximum 1200 mg/day). After 2 weeks on 20 mg/kg/day, dose will be up-titrated to 30 mg/kg/day (maximum 1200 mg/day) and patients will receive this dose for 8 weeks. If intolerable adverse events (AEs) occur, the patient can be down-titrated to the previous dose (only 1 down-titration step will be allowed) or discontinued. After the 8-week maintenance period, the study treatment will be tapered off in 10 mg/kg/day 2 week steps. However, if a patient experiences an increase in seizure frequency (e.g. more than 100% increase vs. baseline) during tapering-off, the patient can proceed directly to the open-label part of the study (Part II).

After completion of the last 2-week 10 mg/kg/day step, patients will have the option to enter a 1 year open-label treatment (Part II) with Eslicarbazepine acetate (up to 30 mg/kg/day, maximum 1200 mg/day), or will have a 4 week observational follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial
Study Start Date : August 2010
Actual Primary Completion Date : March 2012
Actual Study Completion Date : May 2013


Arm Intervention/treatment
Experimental: Eslicarbazepine acetate (BIA 2-093) Drug: Eslicarbazepine acetate (BIA 2-093)
Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
Other Name: Eslicarbazepine acetate

Placebo Comparator: Placebo Drug: Placebo
Treatments will be administered by oral route, once-daily, in the evening.




Primary Outcome Measures :
  1. Change From Baseline in Power of Attention Score to the End of the Double Blind (DB) Period [ Time Frame: Visit 1 (-4 weeks for training), Visit 2 (Day 1), Visit 5 (6 weeks), Visit 7 (12 weeks) or at early discontinuation visit (EDV) ]
    Power of Attention was defined as the sum of the reaction time measures from the attentional tasks (simple [dominant hand only] reaction time, choice reaction time and digit vigilance speed) in order to assess information processing speed and attention/psychomotor speed.Change from baseline to the end of the double-blind period in Power of Attention will be compared between the treatment groups using an ANCOVA. Non-inferiority of ESL vs Placebo will be assessed by comparing the 95% CI's upper bound of the difference of Least Squares Mean (LSmeans) between treatment groups (ESL-placebo) with 121 ms. If the upper bound is greater than 121 ms then the null hypothesis that the change from baseline in the Power of Attention score in ESL group is at least 121 ms inferior than the placebo group will be rejected. Single Values were calculated the average of post treatment visits (visits 5 and 7or EDV) minus average of baseline visits (visits 1 and 2)


Secondary Outcome Measures :
  1. Change From Baseline in Standardized Seizure Frequency - Part I [ Time Frame: Baseline; Titration Period (4 Weeks: V2-V3-V4) ]
  2. Change From Baseline in Seizure Frequency During the One-year Open-Label (OL) [ Time Frame: Weeks 1 to ≥ 41 weeks ]
    Overall Change from Baseline in Seizure Frequency per week for the One-Year Open-Label Period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

At visit 1 (screening), patient must be/have:

  • written informed consent by parent or legal guardian and, where applicable, the patient;
  • age 6 to 16 years, inclusive;
  • a documented diagnosis of epilepsy for at least 12 months prior to screening;
  • at least 2 partial onset seizures during the 4 weeks prior to screening despite treatment with 1 to 2 AEDs in a stable dose regimen;
  • an Intelligence Quotient (IQ) of at least 70;
  • current treatment with 1 to 2 AEDs (except oxcarbazepine, benzodiazepines other than clobazam and vagus nerve stimulation (VNS));
  • excepting epilepsy, patient is judged to be in general good health based on medical history, physical examination and clinical laboratory tests;
  • in the opinion of the investigator, able to complete the Cognitive Drug Research (CDR) test battery;
  • in case of a girl of childbearing potential, patient presents a serum B-human chorionic gonadotropin (B hCG) test consistent with a non gravid state and agrees to remain abstinent or use reliable contraception (if used, hormonal contraception must be combined with a barrier method) starting at screening and continuing until at least the post-study visit (PSV).

At visit 2 (randomisation), patient must be/have:

  • at least 2 partial-onset seizures during the 4 week baseline period prior to randomisation (documented in a diary);
  • in case of a girl of childbearing potential, patient presents a urine B-hCG test consistent with a non-gravid state;
  • stable dose regimen of concomitant AEDs during the 4 week baseline period;
  • diaries satisfactorily completed by the patient or his/her caregiver during the baseline period;
  • satisfactory compliance with the study requirements during the baseline period.

Exclusion Criteria:

At visit 1 (screening), patients must not be/have:

  • only simple partial seizures with no motor symptomatology;
  • primarily generalised seizures;
  • known rapidly progressive neurological disorders (progressive brain disease, epilepsy secondary to progressive cerebral lesion);
  • occurrence of seizures too close to count accurately;
  • history of status epilepticus or cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months prior to screening; seizures of non-epileptic origin;
  • Lennox-Gastaut syndrome;
  • West syndrome;
  • major psychiatric disorders;
  • seizures of psychogenic origin within the last 2 years;
  • history of schizophrenia or suicide attempt;
  • history of attention deficit disorder or other diseases adversely affecting cognitive abilities;
  • currently treated with oxcarbazepine, benzodiazepines other than clobazam (on a routine or chronic basis) and/or VNS;
  • known hypersensitivity to carboxamide derivatives (oxcarbazepine or carbamazepine);
  • uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological or oncology disorder;
  • second or third degree atrioventricular blockade;
  • relevant clinical laboratory abnormalities;
  • estimated creatinine clearance (CLCR) <60 mL/min;
  • pregnancy or nursing;
  • treatment with eslicarbazepine acetate in any previous study;
  • participation in other drug clinical trial within the last 2 months;
  • not ensured capability to perform the trial;
  • any other condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol.

At visit 2 (randomisation), patients must not be / have:

• any condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01527513


Locations
Show Show 36 study locations
Sponsors and Collaborators
Bial - Portela C S.A.
Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT01527513    
Other Study ID Numbers: BIA-2093-208
First Posted: February 7, 2012    Key Record Dates
Results First Posted: October 24, 2014
Last Update Posted: October 24, 2014
Last Verified: October 2014
Keywords provided by Bial - Portela C S.A.:
Partial Epilepsy
eslicarbazepine acetate
Children
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Seizures
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Eslicarbazepine acetate
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action